<acronym id="q2gka"><center id="q2gka"></center></acronym>
<acronym id="q2gka"><center id="q2gka"></center></acronym>



Celebrating more than six decades of Making Cancer History?, The University of Texas M. D. Anderson Cancer Center is located in central Houston on the sprawling campus of the Texas Medical Center. It is one of the world’s most respect

ed centers devoted exclusively to cancer patient care, research, education and prevention.

M. D. Anderson Cancer Center was created in 1941 as a component of The University of Texas System. The institution is one of the nation’s original three comprehensive cancer centers designated by the National Cancer Act of 1971 and is one of 40 National Cancer Institute-designated comprehensive cancer centers today.

In 2009, U.S. News & World Report’s “America’s Best Hospitals” survey ranked M. D. Anderson as the top hospital in the nation for cancer care. M. D. Anderson has achieved the top ranking six times in the past eight years and has ranked as one of the top two hospitals for cancer care for 20 years, since the magazine began its annual survey in 1990.

Since 1944, nearly 800,000 patients have turned to M. D. Anderson for cancer care in the form of surgery, chemotherapy, radiation therapy, immunotherapy, or combinations of these and other treatments. This multidisciplinary approach to treating cancer was pioneered at M. D. Anderson. Because its experts focus on cancer, they are renowned for their ability to treat all types of cancer, including rare or uncommon diseases.








At M. D. Anderson, important scientific knowledge gained in the laboratory is rapidly translated into clinical care. In FY08, the institution invested more than $488 million in research, an increase of about 56 percent in the past five years.

M. D. Anderson ranks first in the number of research grants awarded and total amount of grants given by the NCI. The institution holds 11 NCI grants: brain, breast, genitourinary, head and neck, leukemia, lung, melanoma, ovarian, pancreatic, prostate, uterine. The research program is considered one of the most productive efforts in the world aimed solely at cancer.

M. D. Anderson is expanding its research endeavors with the creation of the McCombs Institute for the Early Detection and Treatment of Cancer. The institute comprises six translational research centers focused on genomics, proteomics, screening, diagnostic imaging and drug development. Located on the 116-acre University of Texas Research Park, about 1.5 miles south of the North Campus, the McCombs Institute will house about 25 percent of M. D. Anderson’s research activities. Four programs are in operation: the Proton Therapy Center, the Cancer Metastasis Research Center, the Center for Cancer Immunology Research and the Kleberg Center for Molecular Markers.


       科研方面:2006年,該中心對科研的投資超過4.1億美元,并在過去的五年中增加了約95 %的投資。 MDACC申請到NCI基金排名第一 。MDACC所擁有10個專業領域的NCI研究基金:膀胱癌,乳腺癌,子宮內膜,頭部和頸部,白血病,肺癌,黑色素瘤,卵巢癌,胰腺癌,前列腺癌。這些研究項目是針對癌癥最有成效的研究。2005年9月, MDACC宣布建立用于研究早期發現和早期治療癌癥的研究所。該研究所由六個獨特的中心集中在基因組學,蛋白質組學,篩選,診斷成像,生物技術和質子治療。坐落在116英畝的得克薩斯大學研究園約1.5公里的主校區。


In FY08, almost 6,000 students, including physicians, scientists, nurses and allied health professionals, took part in M. D. Anderson educational programs. The institution’s School of Health Professions offers bachelor’s degrees in seven allied health disciplines.

More than 1,000 clinical residents and fellows come to M. D. Anderson each year to receive specialized training in the investigation and treatment of cancer. More than 500 graduate students are working on advanced degrees at the Graduate School of Biomedical Sciences, which M. D. Anderson operates jointly with The University of Texas Health Science Center at Houston. More than 1,500 research fellows are being trained in M. D. Anderson’s laboratories.

Thousands more participate in continuing education and distance learning opportunities sponsored by M. D. Anderson, sharing knowledge around the globe. M. D. Anderson provides public education programs to teach healthy people about cancer symptoms and risk factors, giving them information that one day might aid them in making critical health care decisions.


       教育方面:每年超過4300學生在MDACC接受教育,其中包括醫生,科學家,護士和許多保健專業人員。每年超過1000名臨床醫師來MDACC接受專門的培訓。 500多名本科畢業生為了獲得更高的學位來MDACC學習。另外每年有超過1300名的研究人員在MDACC的實驗室中接受培訓。


With faculty and staff working in more than 25 buildings in Houston and central Texas, M. D. Anderson is one of the largest cancer centers in the world. The physical plant includes an inpatient pavilion with 507 beds, five research buildings, three outpatient clinic buildings, two faculty office buildings, a proton radiation clinic building and a patient-family hotel. Since 2005, the Mitchell Basic Sciences Research Building, the Mays Clinic, the Duncan Family Institute for Cancer Prevention, the Saberioon Molecular Markers Research Building, the Proton Therapy Center and the Pickens Academic Tower have opened. An ongoing expansion of Alkek Hospital will accommodate about 200 additional inpatient beds, adding nine floors to its current 12.


       醫院設施:MDACC在休斯頓和得克薩斯州中部擁有25棟樓。MDACC是世界上最大的癌癥中心之一。 住院部有521張病床,五個研究樓,三個門診大樓,一棟員工樓,質子放射治療中心和為病人服務的家庭式酒店。從2005年到現在,米切爾基礎科學和研究大樓,梅斯診所,癌癥預防大樓, 分子標記研究大樓和質子治療中心相繼投入使用。2008年皮肯斯學術大樓開業其中包括額外的教學和行政空間,同時不斷對醫院主樓進行擴建,屆時將增加200張住院病床,增加9個樓層。有17000名員工。


The Institute Gustave-Roussy (IGR), the leading European anticancer centre, assembles on the same site 2,500 men  and women whose missions are to treat patients suffering from cancer, conduct research and develop new therapies, and to pass on knowledge and know-how to the medical and scientific communities in France and world-wide.

In the 400-bed hospital with its 124 statutory physicians, annually over 11,000 new patients are recruited, 130,000 patie

nts attend its clinics and 42,000 patients receive treatment.

Research is conducted by 400 research scientists under the oversight of a scientific council, a therapeutic trials commiss

ion and a clinical research committee.

Situated in the heart of Europe, at the gateway to Paris, the Institute Gustave-Roussy is poised to undergo thorough restructuring and renovation at the beginning of the 21st century, to enhance its efficacy in its primary commitment towards patients, the fight against cancer.


       法國Gustave-Roussy腫瘤醫院和癌癥研究所是歐洲最大的癌癥研究機構,坐落于歐洲的中心——巴黎. 該中心主要致力于癌癥病人的治療,癌癥治療最新技術的研發和推廣. 目前擁有2500名員工、病床數為400、 新病患人數為11000、門診病患數:130000、有42000名患者得到治療。有14個附屬的研究實驗室、300多臨床試驗項目。


National Healthcare Group, in its efforts to help Singapore fight cancer, established The Cancer Institute (TCI) in the ye

ar 2000, to provide comprehensive cancer management programs - from prevention to recovery and long-term health maintenance.